Navigation path

Pharmaceuticals - Union Register


Register of orphan medicinal products


Product information

Polatuzumab vedotin

EU orphan designation number: EU/3/18/2013   
Active ingredient: Polatuzumab vedotin
Indication: Treatment of diffuse large B-cell lymphoma
Sponsor: Roche Registration GmbH
Emil-Barell-Strasse 1, 79639 Grenzach-Wyhlen, Deutschland

   Public summary of scientific opinion    

European Commission proceduresGoto top of the page

Close date procedure Procedure type EMEA number Decision summary publ decision docs annex
18/04/2018 Orphan designation EMA/OD/231/17 (2018)2409 of 16/04/2018
27/07/2018 Transfer of orphan designation EMA/OD/231/17/T/01 (2018)5054 of 25/07/2018